Scilex Holding Company income statement SCLXW

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Scilex Holding Company reported revenue of $30.3 million, down 46.5% from the year before. It recorded a net loss of $374.1 million. The operating loss came to $346.0 million, an operating margin of -1143.7%. Diluted earnings per share were -$36.48. Over the twelve months ended Jun 30, 2026, revenue was $31.6 million and the net loss was $464.6 million. Across the 4 fiscal years shown, revenue shrank from $38.0 million in fiscal 2022 to $30.3 million in fiscal 2025, about 7.3% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Revenue
32
-28.5%
30
-46.5%
57
+21.1%
47
+22.9%
38
—
—
Cost of revenue
14
+7.3%
11
-36.5%
17
+6.4%
16
+45.2%
11
—
—
Gross profit
18
-43.6%
126
+215.3%
40
+28.5%
31
+14.0%
27
—
—
Research and development
19
+41.3%
21
+114.8%
10
-24.4%
13
+40.8%
9
—
—
Selling, general and administrative
278
+145.9%
267
+124.2%
119
-0.5%
120
+84.4%
65
—
—
Operating income
-359
-271.5%
-346
-314.9%
-83
+20.9%
-105
-108.2%
-51
-41.3%
-36
—
Foreign currency gain (loss)
-0
-92.2%
0
+291.1%
-0
+61.9%
-0
-78.8%
-0
—
—
Other income (expense)
-105
-28
-364.6%
11
+219.1%
-9
-132.6%
27
—
—
Pretax income
-465
-473.8%
-374
-413.7%
-73
+36.3%
-114
-389.4%
-23
—
—
Income tax
0
-22.2%
0
+2700.0%
-0
-107.7%
0
+225.0%
0
—
—
Net income
-465
-473.7%
-374
-413.8%
-73
+36.3%
-114
-389.3%
-23
+73.6%
-88
-86.1%
-48
Net income to common
-448
-264.5%
-402
-452.8%
-73
+56.4%
-167
—
—
—
Basic EPS
194.28
+1005.9%
-36.48
-403.9%
-7.24
-465.6%
-1.28
-652.9%
-0.17
+74.6%
-0.67
—
Diluted EPS
194.28
+1005.9%
-36.48
-353.2%
-8.05
-528.9%
-1.28
-652.9%
-0.17
+74.6%
-0.67
—
Weighted average shares, basic
-2
-140.2%
0
+9.7%
0
-100.0%
130
-2.9%
134
+1.0%
133
—
Weighted average shares, diluted
-2
-140.2%
0
+8.8%
0
-100.0%
130
-2.9%
134
+1.0%
133
—
Other measures
Depreciation and amortization
8
+106.8%
5
+14.3%
4
-2.4%
4
+4.7%
4
—
—
EBITDA
-351
-278.6%
-341
-330.2%
-79
+21.7%
-101
-117.0%
-47
—
—
Interest coverage
-20.12x
-30.20x
-42.48x
—
—
—
—
Margins
Gross margin
55.50%
415.83%
70.51%
66.45%
71.61%
—
—
Operating margin
-1,136.40%
-1,143.71%
-147.37%
-225.55%
-133.13%
—
—
Pretax margin
-1,469.71%
-1,236.33%
-128.66%
-244.57%
-61.42%
—
—
Profit margin
-1,469.76%
-1,236.42%
-128.66%
-244.59%
-61.43%
—
—
EBITDA margin
-1,110.09%
-1,128.43%
-140.22%
-216.68%
-122.71%
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
SCLX (Nasdaq), SCLXW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Palo Alto, CA
SEC filer status
, Emerging growth company
SEC CIK
1820190
Former names
Scilex Holding Company/DE (until Nov 30, 2022); Vickers Vantage Corp. I (until Nov 15, 2022)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.